Seeport » MarketPlace
Advanced Search
Search Marketplace

MarketPlace

Biotechnology/Pharmaceutical Tags: Nanoprobes
IPC:A61P
NAICS:54710

Nanogold-Enhanced Head & Neck Cancer

Nanoprobes, Inc

  • Technology Description

    According to the American Academy of Otolaryngology, more than 55,000 Americans will develop cancer of the head, and nearly 13,000 of them will die this year from it.[1] Improved treatments are desperately needed. In conventional radiotherapy, there is a delicate challenge to deliver a high therapeutic radiation dose to the tumor without affecting the surrounding healthy tissues. “Dose enhancement at interfaces between high and low atomic number (Z) materials has been studied for over 50 years.”[2] “High-Z elements absorb X-rays and increase local dose,”[3] Nanoprobes has extended this concept and is developing Nanogold (novel gold nanoparticle) for enhanced-radiotherapy. “In preliminary studies, high levels of gold specifically accumulated in tumors after intravenous injection of Nanogold. X-ray irradiation then resulted in dramatic tumor regressions and long term survivals (86%, >1yr) in mice compared with mice irradiated without Nanogold (20%).

  • Market Projection

    56?rand=871719
    2006 2007 2008 2009 2010
    Market Size $800000000.0 $900000000.0 $1000000000.0 $1100000000.0 $1300000000.0
    Market Share (%) 0.0% 1.0% 2.0% 3.0% 10.0%

  • Value Proposition

    Nanogold radiotherapy offers several advantages over iodine-based agents. Nanogold “may be administered locally or systemically,” prior to local application of radiation. Since nanogold is non-toxic, this approach enhances radiation toxicity to the irradiated area. “This is in contrast to administration of toxic chemotherapy drugs that may affect other critical organs such as liver, kidney, and bone marrow.” Furthermore, nanogold effect is tumor specific, meaning nanogold “preferentially accumulates in tumors, especially in the vasculature. The high mitotic index of tumor and tumor endothelial cells makes them especially vulnerable to radiation enhancement, since the gold is in the expanded tumor blood volume and extravasates through the leaky tumor vasculature.”

  • Competitive Analysis

    55?rand=158759

  • Video Introduction

  • Commercialization Team

  • Company Capsule

    Nanoprobes, Inc

    95 Horse Block Road
    Yaphank, NY 11980

    (631) 205-9490
    www.nanoprobes.com

    Nanoprobes was founded to develop the most sensitive reagents and technology for detecting biological molecules. Our unique gold labeling technology uses chemically cross-linked metal clusters and nanoparticles as labels. Unlike conventional immunogold probes, in which colloidal gold particles are electrostatically adsorbed to antibodies and proteins, our gold labels are uncharged molecules which are cross-linked to specific sites on biomolecules. This gives our probes a range and versatility which is not available with colloidal gold. Our labels can be attached to any molecule with a reactive group -- proteins, peptides, oligonucleotides, small molecules and lipids -- for detection and localization. Other labels can be combined with our gold labels; our unique FluoroNanogold probes combine Nanogold® and fluorescein into a single probe for imaging a specimen both by fluorescence and electron microscopy. New probes can be engineered based on any fragment of a naturally occurring biomolecule, and the label can be positioned away from the binding site so it does not interfere with binding. Our 1.4 nm Nanogold® probes have been cited in over 80 publications, and we are now developing larger cross-linkable labels in order to offer our customers larger covalently linkable probes with the same advantages.